Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Organisation › Details

GigaGen Inc.

GigaGen is a biopharmaceutical company that develops novel antibody therapies derived from immune repertoires. GigaGen’s technology platform captures the genetic make-up of entire immune repertoires, genetically analyzing B cells at a rate of millions per hour, while simultaneously identifying their antigen and protein binders. GigaGen has drug discovery projects with several pharmaceutical companies in addition to its own pipeline for development of the first recombinant intravenous immunoglobulin (IVIG) and immuno-oncology therapies. *

 

Period Start 2017-07-05 existent
Products Industry therapeutic antibody
  Industry 2 biopharmaceutical
     
Region Region South San Francisco, CA
  Country United States (USA)
  Street 407 Cabot Road
  City 94080 South San Francisco, CA
    Address record changed: 2017-07-13
     
Basic data Employees n. a.
     
    * Document for �About Section�: Grifols S.A.. (7/5/17). "Press Release: Grifols Strengthens Its R&D+i through Investee Companies. Grifols Opens New Lines of Research with the Acquisition of a 44% Stake in GigaGen for USD 35 Million". Barcelona.
     
   
Record changed: 2018-10-31

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for GigaGen Inc.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81




» top